Recently Featured

Biotech Leaders Campaign for Rick Pazdur as Next FDA Commissioner; Takeda Announces 4,500 Layoffs

June 6, 2026
In a significant move within the biotech sector, hundreds of industry executives and investors are advocating for Rick Pazdur to assume the role of FDA commissioner. This push underscores a growing desire for leadership that prioritizes innovation and regulatory efficiency in drug approval processes, particularly as the industry faces increasing scrutiny over drug development timelines…

Nonprofits collaborate to launch marketplace for shelved CGTs

June 6, 2026
In a significant development for the gene and cell therapy landscape, a coalition of nonprofit organizations has announced the launch of a marketplace aimed at reviving shelved cell and gene therapy (CGT) programs. This initiative, highlighted by OTXL’s COO Beth White, is designed to breathe new life into CGT projects that have been stalled due…

Roche’s ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod

June 6, 2026
Roche has secured FDA approval for the expanded use of Tecentriq in post-surgical bladder cancer, leveraging its innovative ctDNA-guided strategy in collaboration with Natera’s Signatera as a companion diagnostic. This approval marks a significant milestone in the treatment landscape for bladder cancer, where precision medicine is increasingly becoming a focal point in therapeutic development. The…

Aardvark to Unblind Rare Disease Trial Following Clinical Hold

June 6, 2026
Aardvark Pharmaceuticals is set to unblind its rare disease trial after receiving a full clinical hold from the FDA on its candidate. This decision comes after the agency raised concerns regarding the safety profile of the drug, which has significant implications for Aardvark’s development timeline and investor confidence. The unblinding process will allow the company…

Ongoing Cases